Summary
In chronic lymphocytic leukemia, progression-free survival in minimal residual disease–negative patients can be best predicted using a combination of minimal residual disease and the clinical response. The combination is more accurate than clinical response alone. Assessment using only splenomegaly has no influence on progression-free survival prediction.
- progression-free survival
- peripheral blood
- prediction
- fludarabine
- cyclophosphamide
- rituximab
- bendamustine
- © 2014 SAGE Publications